Delhi AIIMS Sets up Committee for Patient Safety and Pharmacovigilance

Written by Medical Dialogues Team Published On 2025-03-21T09:30:37+05:30 | Updated On 21 March 2025 9:30 AM IST

New Delhi: In a move to enhance patient safety and strengthen pharmacovigilance, the All India Institute of Medical Sciences (AIIMS), New Delhi, has set up a dedicated committee to monitor and report adverse events related to drugs and medical devices used in patient care. This initiative aims to strengthen pharmacovigilance by systematically tracking side effects, complications, and safety issues arising during medical interventions at the institute.

The committe will collect and analyze data on adverse reactions and forward regular reports to central authorities. The goal is to identify potential safety issues with drugs and medical devices, facilitating timely regulatory actions to mitigate risks.

Also Read: AIIMS Delhi Introduces advanced surgical robot in General Surgery department

Dr. Pooja Gupta has been appointed as the coordinator of the committee, with Dr. Sudhir Chandra Sarangi serving as the deputy coordinator. The committee will also consist of six additional members, including prominent AIIMS experts such as Dr. Nirupam Madan, Medical Superintendent; Dr. D.S. Arya, Head of the Pharmacology Department; Dr. Manish Juneja from the Medicine Department; Dr. Kanika Jain from Hospital Administration; and Dr. Sudhir Chaudhary.

In an official statement, AIIMS highlighted that the committee would play a crucial role in overseeing the collection and evaluation of adverse event reports. These reports will be forwarded to the National Centre at the Indian Pharmacopoeia Commission (IPC) in Ghaziabad for further assessment and regulatory action. The initiative encourages doctors, nurses, and paramedical staff to actively report adverse events to the Pharmacology Department, ensuring a smooth and efficient flow of information to the appropriate national programs.

Also Read: AIIMS Satellite Centre in Ghaziabad gets 10-acre land approval

As per the recent media report by TNIE, “This committee will collect and analyze adverse effect data and send regular reports to the National Centre at Indian Pharmacopoeia Commission at Ghaziabad. The committee will also expand and optimize the patient safety activities in the institute,” an order copy by AIIMS read.

Monitoring the safety of medical treatments is a vital ethical responsibility for healthcare professionals. According to the news reports, Adverse Events Monitoring (AEM) allows medical teams to identify and report side effects, facilitating timely interventions to minimize risks and safeguard patient health. This system also benefits pharmaceutical manufacturers by helping them detect safety concerns related to drugs and medical devices, enabling them to implement necessary improvements.

AIIMS Delhipharmacovigilancedrug side effectsAll India Institute of Medical Sciences

Medical Dialogues Team